glp 1 taken off market The Multi-Sector Impacts of GLP-1RA Drugs Why 2026 Will Reshape Access

doi: 10.1016/0196-9781(91)90007-c

In August 2025, Novo Nordisk announced that the FDA has approved WEGOVY as the first GLP-1 receptor agonist for adults with Metabolic Dysfunction-associated Steatohepatitis (MASH) who have moderate to advanced fibrosis, excluding cirrhosis, in combination with diet and exercise

Such peptides have advanced to clinical evaluation and inspired the pursuit of multiple related approaches to achieving polypharmacy within single molecules

Over time, however, scientists discovered that GLP-1 is not merely a peripheral metabolic hormone

Regular Exercise Physical activity is another essential component of a healthy lifestyle

S.DeenW